The firms mentioned above that provide fake peer reviews all result from countries and China in Southeast Asia, & most of the authors involved in these cases result from the same areas. But it would be a mistake to check out this as a Chinese or Asian problem. The nagging problem may be the perverse incentive systems in scientific publishing. So long as authors are rewarded for publishing many articles and editors are rewarded for publishing them quickly, new ways of gaming the traditional publication models will be invented more quickly than new control steps could be put in place..The agreement gives Pfizer rights to commercialize antibodies generated from the collaboration. Adimab will receive upfront payments. In addition, Adimab is permitted receive preclinical milestones, clinical development milestones, commercial milestones, licensing fees and royalties on therapeutic and diagnostic revenue. Also in a separate agreement, Adimab and an undisclosed organization have initiated a study program whereby Adimab use its proprietary discovery platform to recognize fully individual antibodies against one oncology target selected by the undisclosed business. The agreement provides undisclosed company rights to commercialize antibodies generated from the collaboration. Adimab shall receive upfront payments, preclinical milestones and licensing charges. In addition, Adimab is permitted receive clinical development milestones, commercial milestones and royalties on therapeutic and diagnostic product sales.